Venture Capital

CHAOS: €2 Million Closed To Accelerate AI-Driven Expansion Across Europe’s Real Estate Market

By Amit Chowdhry ● Nov 16, 2025

CHAOS, a Helsinki location intelligence company focused on transforming real estate decision-making through AI, has closed a €2 million funding round to expand its platform across the Nordics and the DACH region. The round included continued backing from its largest investor, Swedish investment company Nidoco, along with participation from Finnvera, the State of Finland’s specialized financing institution.

Gate Bioscience: $65 Million Series B Closed To Advance Oral Molecular Medicines Into Clinical Trials

By Amit Chowdhry ● Nov 16, 2025

Gate Bioscience has closed a $65 million oversubscribed Series B financing round to accelerate the advancement of its emerging class of oral small-molecule medicines, known as molecular gates. The round brings the company’s total capital raised to $135 million, positioning the Brisbane-based biotechnology company to enter the clinic with programs targeting high-value inflammatory and neurological disease proteins.

Scorbit: Over $5 Million Seed Funding Raised As Beta Launch Accelerates Market Momentum

By Amit Chowdhry ● Nov 16, 2025

Scorbit, a connected gaming platform merging physical arcade play with online community and competition, has closed a seed round totaling more than $5 million after achieving rapid traction in its beta phase. The round was led by Detroit Venture Partners, with participation from Grand Ventures, Weiser Family Office, Michigan Rise / Red Cedar, Invest Detroit Ventures, Eberg Capital, Ann Arbor SPARK Capital, Mudita Venture Fund II LLC, Precursor Ventures, Side Door Ventures, Wakestream, Gambit Ventures, and a broad mix of individual and angel investors.

Virometix: $15 Million Financing Raised To Advance Clinical Development Of Synthetic Pneumococcal Vaccine V-212

By Amit Chowdhry ● Nov 16, 2025

Virometix AG has secured a $15 million financing round from its existing shareholders, marking a significant milestone for the Swiss biotechnology company as it accelerates the clinical and developmental progress of its lead synthetic vaccine candidate, V-212. The company, based in Schlieren and focused on next-generation fully synthetic vaccines, confirmed the raise as V-212 continues through its Phase I clinical evaluation.

Karpowership: $400 Million In Oversubscribed Syndicated Portfolio Financing Closed

By Amit Chowdhry ● Nov 16, 2025

Karpowership has completed a significant financial milestone with the closing of a $400 million syndicated facility for its affiliate Sea World Energy Holdings Limited. The Mauritius Commercial Bank served as the Sole Mandated Lead Arranger and Account Bank for the transaction, which represents the company’s first portfolio financing and a significant advancement in its long-term capital strategy.

PeptiSystems: Major Growth Equity Investment Raised From Rubicon Healthcare Partners

By Amit Chowdhry ● Nov 16, 2025

PeptiSystems has secured a significant growth equity investment from Rubicon Healthcare Partners, marking a pivotal step in the company’s plan to expand its commercial presence and scale its advanced manufacturing technologies for peptide and oligonucleotide therapeutics. The investment positions Rubicon as the largest shareholder in the Uppsala-based life science company. It provides new capital to accelerate both international expansion and the development of next-generation manufacturing solutions for a rapidly growing biopharmaceutical market.

Monomoy: Third Credit Opportunities Fund Closed Above $500 Million Target

By Amit Chowdhry ● Nov 16, 2025

Monomoy Capital Partners has closed its third credit opportunities fund, reaching a total of more than $500 million in commitments, marking a significant milestone for the New York–based private investment firm as it continues to expand its middle-market credit strategy. The raise was completed in just 10 months and represents a growth rate of more than 70% compared to Monomoy Credit Opportunities Fund II, which closed in 2023. The firm achieved this result despite a challenging fundraising climate, drawing strong participation from returning investors, as well as a broad range of new global limited partners.

CHAOS Industries: $510 Million Raised To Accelerate Expansion And Advance Next-Generation Defense Systems

By Amit Chowdhry ● Nov 16, 2025

CHAOS Industries has closed a $510 million funding round led by Valor Equity Partners, marking one of the most significant recent investments in defense technology and valuing the company at $4.5 billion. The Los Angeles-based firm, known for developing Coherent Distributed Networks (CDN) that provide warfighters critical time to respond to threats, has now raised more than $1 billion in just three years. The new funding will support expanded product development and accelerated manufacturing as global drone activity intensifies.

Booster Therapeutics: $5 Million Grant Secured From The Michael J. Fox Foundation

By Amit Chowdhry ● Nov 16, 2025

Booster Therapeutics has received a $5 million research grant from The Michael J. Fox Foundation for Parkinson’s Research. The award, part of the Foundation’s Therapeutics Pipeline Program, will accelerate the development of a new class of small-molecule proteasome activator medicines aimed at restoring the cell’s natural quality control systems and clearing harmful proteins associated with Parkinson’s and other complex diseases.

Beacon Biosignals: $86 Million Series B Raised To Advance AI-Driven Neurodiagnostics And Precision Neuroscience

By Amit Chowdhry ● Nov 16, 2025

Beacon Biosignals has raised an oversubscribed $86 million Series B to accelerate the clinical adoption of AI-powered biomarkers for neurological and psychiatric disease, expand its precision medicine data platform, and scale its neurodiagnostic infrastructure. The financing was backed by Innoviva, Google Ventures (GV), Nexus NeuroTech Ventures, S32, Catalio Capital Management, and Takeda, with continued participation from General Catalyst, Logos Capital, Casdin Capital, and Indicator Ventures. This new capital brings the company’s total funding to over $121 million.

Azumuta: €8 Million Series A Closed To Advance AI-Driven Digital Work Instructions For Global Manufacturers

By Amit Chowdhry ● Nov 16, 2025

Azumuta, a Ghent-based software scale-up focused on digitalizing frontline manufacturing operations, has secured €8 million in Series A funding to accelerate development of its operator-centric platform. The financing round was led by Keen Venture Partners, with participation from Capricorn Partners and returning investors PMV, Angelwise, and Dirk Vermunicht.

4TEEN4 Pharmaceuticals Extends Series C To €55 Million To Advance Clinical Development Of Procizumab In Cardiogenic Shock

By Amit Chowdhry ● Nov 16, 2025

4TEEN4 Pharmaceuticals has expanded its Series C financing round to €55 million, securing participation from both existing and new investors to accelerate the development of its lead monoclonal antibody therapy, procizumab, for patients suffering from cardiogenic shock. The company will use the additional capital to support further its ongoing multicenter Phase 2a PROCARD 2a clinical trial, broaden the study footprint across Europe, and prepare for planned expansion into the United States.

Vida: $4 Million Series A Raised To Expand AI Voice Technology And Strengthen Executive Leadership

By Amit Chowdhry ● Nov 16, 2025

Vida announced the close of a $4 million Series A funding round that will accelerate the company’s AI voice innovation and support its expansion into new industries as demand for automated customer communication solutions continues to grow. Trammell Venture Partners led the round with participation from Timechain and others, adding new strategic backing as Vida’s AI phone agents surpass one hundred million customer interactions.

RE2Sources: Italian Biomethane Platform Raises Strategic Investment From VisionEdgeOne

By Amit Chowdhry ● Nov 16, 2025

VisionEdgeOne has completed a significant new investment in Italy’s growing renewable gas sector, becoming a joint-controlling co-investor in RE2Sources alongside Arjun Infrastructure Partners. The investment was made through the VisionEdgeOne Infrastructure Partnership platform and marks a substantial expansion of VE1’s presence in mid-market sustainable infrastructure.